Pre-Course Offerings

Wednesday, October 10, 2018
Message from Planning Committee Chair

Dear Colleagues:
The ASAM 2018 State of the Art Course in Addiction Medicine delivers an exciting overview and insight into the scientific advances and emerging evidence in addiction medicine. The program this year includes the most pressing issues identified by the nations’ top scientists and leading clinicians who labor daily to improve outcomes for patients with substance use disorders.

The course is divided into ten sessions, each filled with presentations that dive deep into the most pressing clinical issues. The objective of each session is to expand upon highly relevant topics that today’s addiction specialists face in their practice. Researchers and clinical experts will deliver these presentations in a condensed and informative format that will encompass relevant clinical information and recent scientific advances. Discussion and interactive audience participation will follow each presentation for an engaging learning experience.

This is my last year serving as Chair of the Program Planning Committee, and I would like to thank all the committee members and everyone who made this program possible. It has been an honor to serve as your committee Chair.

Throughout the next three days you will have the opportunity to learn from and network with addiction leaders and researchers. On behalf of the Program Planning Committee, thank you for joining us as we explore Scientific Advances and Emerging Evidence in Addiction Medicine.

Sincerely,

Frank J. Vocci, PhD, Chair

Program Planning Committee

Frank J. Vocci, PhD, Chair
Daniel P. Alford, MD, MPH, FACP, DFASAM
Kathleen T. Brady, MD, PhD
Ron R. Flegel, BS, MT (ASCP), MS, SAMHSA Representative, CSAP
Petra Jacobs, MD, MHS, NIDA Representative
Chideha M. Ohuoha, MD, MPH, SAMHSA Representative, CSAT
Richard K. Ries, MD, FAPA, DFASAM
Diedra Roach, MD, NIAAA Representative
R. Corey Waller, MD, MS, FACER, DFASAM

Learning Objectives

Upon completion, participants should be able to:

• Identify the latest epidemiology and prescribing guidelines for opioids and treatment approaches for opioid use disorder.
• Identify the latest trends in marijuana legislation, policy, testing, synthetic cannabinoids, and implications for practice.
• Explain how animal models are being used to develop medications for stimulant use disorders.
• Describe the implications of excessive alcohol use in adolescents, young adults, and women of child bearing potential.
• Apply suicide screening and interventions to reduce self-harm in substance-dependent populations.
• Refer to behavioral therapies and understand how they are being integrated into new technologies.

Continuing Medical Education Credits

ASAM has been awarded the highest level of Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME).

Accreditation Council for Continuing Medical Education (ACCME)
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ASAM State of the Art Course in Addiction Medicine
The American Society of Addiction Medicine designates this live activity for a maximum of 19 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an on-line evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 18 LLSA credits towards ABPM MOC Part II requirements.

ABAM Transitional Maintenance of Certification (Tmoc)
The ASAM 2018 State of the Art Course in Addiction Medicine and its two pre-courses have been approved by the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

Network:
“Renaissance_CONFERENCE”
Password: ASAMSOA18
## PRE-COURSE OFFERINGS

**WEDNESDAY, OCTOBER 10, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Offerings</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 am - 7:30 pm</td>
<td>Open Registration &amp; Information Area</td>
<td>Congressional Registration, Ballroom Level</td>
</tr>
<tr>
<td>12:30 pm – 4:45 pm</td>
<td>The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements</td>
<td>R. Corey Waller, MD, MS, FACEP, DFASAM</td>
</tr>
<tr>
<td>5:30 pm – 8:00 pm</td>
<td>The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits</td>
<td>R. Corey Waller, MD, MS, FACEP, DFASAM</td>
</tr>
<tr>
<td>8:30 pm – 9:30 pm</td>
<td>Mutual Help Meeting Peer-run problem-specific addiction support group meeting</td>
<td>Lafayette, Ballroom Level</td>
</tr>
</tbody>
</table>

## STATE OF THE ART COURSE IN ADDICTION MEDICINE

**THURSDAY, OCTOBER 11, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Offerings</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am - 6:30 pm</td>
<td>Open Registration &amp; Information Area</td>
<td>Congressional Ballroom A-C, Ballroom Level</td>
</tr>
<tr>
<td>7:00 am - 7:45 am</td>
<td>Continental Breakfast Network with Exhibitors, Colleagues &amp; Experts</td>
<td>Congressional Registration, Ballroom Level</td>
</tr>
<tr>
<td>7:45 am - 8:00 am</td>
<td>Opening – Day One Welcome, Introductions &amp; Opening Remarks</td>
<td>Kelly J. Clark, MD, MBA, DFAPA, DFASAM; R. Corey Waller, MD, MS, FACEP, DFASAM</td>
</tr>
</tbody>
</table>

### Session 1: The Opioid Crisis: Current Status and Treatment Responses

Organized and Moderated by Daniel P. Alford, MD, MPH, FACP, DFASAM

This session will examine several topics in the field of opioid-related morbidity and mortality, as well as the treatment of opioid use disorder. Presenters will delve into updates on opioid misuse, overdose epidemiology, and current national trends. This will be followed by an updated review of evidence-based strategies for opioid overdose prevention, and an overview of data that are the basis of current approaches for the investigation of novel kappa-opioid receptor ligands for the treatment of opioid use disorder. Finally, we will close with a review of recent clinical trials examining the efficacy and effectiveness of extended-release (XR) medications for the treatment of opioid use disorder.

<table>
<thead>
<tr>
<th>Time</th>
<th>Offerings</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am - 8:30 am</td>
<td>Opioid Epidemiology in the Age of Fentanyl</td>
<td>Richard C. Dart, MD, PhD</td>
</tr>
<tr>
<td>8:30 am - 9:00 am</td>
<td>Opioid Overdose Prevention and Management in a Dynamic Opioid Crisis</td>
<td>Alexander Y. Walley, MD, MSc, FASAM</td>
</tr>
<tr>
<td>9:00 am - 9:30 am</td>
<td>Targeting the Kappa-Opioid Receptor System for Developing New Pharmacotherapies for Opioid Use Disorder</td>
<td>Eduardo R. Butelman, PhD</td>
</tr>
<tr>
<td>9:30 am - 10:00 am</td>
<td>Long-Acting Naltrexone and Buprenorphine Formulations: Efficacy, Effectiveness, and Comparative Effectiveness</td>
<td>Joshua D. Lee, MD, MSc</td>
</tr>
<tr>
<td>10:00 am - 10:30 am</td>
<td>Refreshment Break Network with Colleagues, Experts, &amp; Exhibitors</td>
<td>Congressional Ballroom A-C, Ballroom Level</td>
</tr>
</tbody>
</table>

**CME Committee, Medical Education Council (MEC), Program Planning Committee, and Faculty Disclosure Information**

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the CME Committee, MEC, Planning Committees, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
**Thursday, October 11, 2018**

---

**THURSDAY, OCTOBER 11, 2018 (CONTINUED...)**

All Sessions will be held in Grand Ballroom, Ballroom Level

**Session 2: Cocaine: How the Cellular Basis of its Impact Tells the Story**

Organized by R. Corey Waller, MD, MS, FACEP, DFASAM and Petra Jacobs, MD, MHS

Moderated by R. Corey Waller, MD, MS, FACEP, DFASAM

Not just for the 80's stock broker anymore! The subcellular pharmacokinetics make this a particularly difficult substance to treat. We will walk through the advanced neuroscience, the animal models that define our predictive understanding, and the behavioral aspects of both the pathology and treatment. While opioids have captured recent headlines, cocaine and its close cousin methamphetamine have been smoldering in the background. Although we do not have medications with good evidence for treatment, we can predict the withdrawal syndrome and the behaviors that drive utilization. With this knowledge we can build better interventions that are both helpful and reimbursed.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am - 11:00 am</td>
<td>Is New York the Only Place Snorting Coke These Days?</td>
<td>R. Corey Waller, MD, MS, FACEP, DFASAM</td>
</tr>
<tr>
<td>11:00 am - 11:30 am</td>
<td>Activation of a Dopamine Receptor Complex in Brain Attenuates Cocaine Reward and Drug Seeking</td>
<td>Susan R. George, MD, FRCP(C), FACP</td>
</tr>
<tr>
<td>11:30 am - 12:00 pm</td>
<td>Modification of Motivation and Mood Pathways in Cocaine Addiction</td>
<td>Antonello Bonci, MD</td>
</tr>
<tr>
<td>12:00 pm - 12:30 pm</td>
<td>So We Got No Meds, Now What Do We Do?</td>
<td>Ned J. Presnall, LCSW</td>
</tr>
<tr>
<td>12:30 pm – 1:30 pm</td>
<td>Lunch (Provided)</td>
<td>Congressional Ballroom A-C, Ballroom Level</td>
</tr>
</tbody>
</table>

**Session 3: Implications of Expanded Cannabis Access**

Organized by Ron R. Flegel, BS, MT (ASCP), MS and Petra Jacobs, MD, MHS

Moderated by Ron R. Flegel, BS, MT (ASCP), MS

This session will examine several topics in the field of cannabinoids and cannabis access. This will involve presentations on the epidemiology of cannabis use and cannabis use disorder, followed by an update on cannabis decriminalization, legalization, and use of "medical marijuana" and current laws. Then we will dive into routes of administration, detailed information on "synthetic marijuana," and the use and consequenc-es thereof. The presentations will describe the consequences of expanded marijuana access in terms of adolescent use, traffic accidents, and marijuana testing in the workplace in states with and without legalization as emerging issues.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 pm - 2:00 pm</td>
<td>Epidemiology of Cannabis Use and Cannabis Use Disorder</td>
<td>Deborah S. Hasin, PhD</td>
</tr>
<tr>
<td>2:00 pm - 2:30 pm</td>
<td>Reefer Madness? Update on Cannabis Laws and &quot;Medical Marijuana&quot;</td>
<td>D. Faye Caldwell, JD</td>
</tr>
<tr>
<td>2:30 pm - 3:00 pm</td>
<td>Routes of Marijuana Administration and Testing</td>
<td>Ryan G. Vandrey, PhD</td>
</tr>
<tr>
<td>3:00 pm - 3:30 pm</td>
<td>Biological Effects of Synthetic Cannabinoid Drugs Found in the Street Drug Marketplace</td>
<td>Michael H. Baumann, PhD</td>
</tr>
<tr>
<td>3:30 pm - 4:00 pm</td>
<td>Refreshment Break</td>
<td>Congressional Ballroom A-C, Ballroom Level</td>
</tr>
</tbody>
</table>

---

**Special thanks to these Federal Agency Program Partners:**

- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute on Drug Abuse (NIDA)
- Substance Abuse and Mental Health Services Administration (SAMHSA)
- Food and Drug Administration (FDA)
**THURSDAY, OCTOBER 11, 2018 (CONTINUED...)**

**Session 4: Cannabis and Coexisting Disorders**
Organized by Petra Jacobs, MD, MHS and Ron R. Flegel, BS, MT (ASCP), MS
Moderated by Petra Jacobs, MD, MHS

This session will examine several topics in the field of cannabinoids, cannabinoid use, and coexisting disorders. As a continuation of cannabis topics, this session will conclude with a presentation on advances in pharmacotherapies for cannabis use disorders, the impact and effect of marijuana use on treating other substance use disorders, consequences of expanded marijuana use on opioid usage, and the CBD products.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 pm - 4:30 pm</td>
<td>Advances with Pharmacotherapies for Cannabis Use Disorder</td>
</tr>
<tr>
<td>4:30 pm - 5:00 pm</td>
<td>Impact of Marijuana Use on Treating Other Substance Use Disorders</td>
</tr>
<tr>
<td>5:00 pm - 5:30 pm</td>
<td>The Public Health Impacts of Expanded Cannabis Access</td>
</tr>
<tr>
<td>5:30 pm - 6:30 pm</td>
<td>Reception A “Monumental” Experience of Networking and Fun with Colleagues, Experts, and Exhibitors</td>
</tr>
<tr>
<td>6:30 pm - 8:00 pm</td>
<td>Corporate Roundtable Meeting (By Invitation Only)</td>
</tr>
<tr>
<td>8:00 pm - 9:00 pm</td>
<td>Mutual Help Meeting Peer-run problem-specific addiction support group meeting</td>
</tr>
</tbody>
</table>

**FRIDAY, OCTOBER 12, 2018**

**Session 5: Breaking Down Barriers that Block Quality Care**
Organized and Moderated by Chideha M. Ohuoha, MD, MPH and R. Corey Waller, MD, MS, FACEP, DFASAM

I am not sure why we are even having this session? I mean, we have access to treatment on demand, everyone knows the evidence, there is ample funding for treatment, and thank goodness that everyone screens for addiction in their practice. Maybe we would need this session if there was stigma, but everyone agrees that addiction is a chronic brain disorder and are competing for treatment centers to open in their neighborhoods. Really, thank goodness that medical schools and residency programs spend a lot of time training new physicians for the complexity of this disease and how to treat it. Because of this, we have a vibrant, motivated workforce just waiting for the next addiction patient. So, I am not sure what we are going to discuss, but it would be great if we had an audience for our speakers.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am - 8:30 am</td>
<td>The Federal Policy Response to Removing Barriers</td>
</tr>
<tr>
<td>8:30 am - 9:00 am</td>
<td>If Getting into the US Was Like Getting into Addiction Treatment, We Wouldn't Need a Wall</td>
</tr>
<tr>
<td>9:00 am - 9:30 am</td>
<td>Buprenorphine Prescribing: Getting to Yes</td>
</tr>
<tr>
<td>9:30 am - 10:00 am</td>
<td>Audience Discussion with Panelists</td>
</tr>
<tr>
<td>10:00 am - 10:30 am</td>
<td>Refreshment Break Network with Colleagues, Experts, &amp; Exhibitors</td>
</tr>
</tbody>
</table>
**FRIDAY, OCTOBER 12, 2018 (CONTINUED)**

All Sessions will be held in Grand Ballroom, Ballroom Level

### Session 6: Alcohol and Opioid Use in Women and Girls: Health Impacts and Treatment
Organized and Moderated by Diedra Roach, MD

Drinking too much alcohol can seriously affect the health of women and girls. Excessive alcohol use increases the risk of certain types of cancers, heart disease, sexually transmitted diseases, unintended pregnancy, and many other health problems. This session will highlight findings from current research on drinking among women and girls.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am - 10:50 am</td>
<td>US Trends in Harmful Substance Use Among Women and Girls</td>
<td>Deborah S. Hasin, PhD</td>
</tr>
<tr>
<td>10:50 am - 11:10 am</td>
<td>Alcohol and the Female Brain</td>
<td>George F. Koob, PhD</td>
</tr>
<tr>
<td>11:10 am - 11:30 am</td>
<td>Harmful Effects of Alcohol and Opioid Use in Women and Girls</td>
<td>Rajita Sinha, PhD</td>
</tr>
<tr>
<td>11:30 am - 11:50 am</td>
<td>Health Impacts of Maternal Alcohol Use</td>
<td>Grace Chang, MD, MPH</td>
</tr>
<tr>
<td>11:50 am - 12:10 pm</td>
<td>Implementation and Outcomes of Screening and Brief Intervention for Women in Primary Care</td>
<td>Constance M. Weisner, DrPH, LCSW</td>
</tr>
<tr>
<td>12:10 pm – 12:30 pm</td>
<td>Do Women Benefit from Specialty Treatment for Alcohol and Drug Use Disorders?</td>
<td>Mary E. McCaul, PhD</td>
</tr>
<tr>
<td>12:30 pm – 1:30 pm</td>
<td>Lunch (Provided)</td>
<td>Grab Lunch and Network with Colleagues, Experts, &amp; Exhibitors</td>
</tr>
</tbody>
</table>

### Addressing Emerging Issues and Advances in Addiction Medicine: Fireside Chat
Moderated by Kelly J. Clark, MD, MBA, DFAPA, DFASAM, ASAM President

An informal Fireside Chat with federal agency representatives. Agency leaders will each give a five-minute overview from their respective organizations about emerging issues and advances in addiction medicine, increasing the addiction medicine workforce, and improving the quality of care for patients. Dr. Clark will engage each representative in a lively conversation.

1:30 pm - 2:30 pm

- George F. Koob, PhD
  Director
  National Institute on Alcohol Abuse and Alcoholism (NIAAA)

- Wilson M. Compton, MD, MPE
  Deputy Director
  National Institute on Drug Abuse (NIDA)

- Anita Everett, MD
  Chief Medical Officer
  Substance Abuse and Mental Health Services Administration (SAMHSA)

- Janet Woodcock, MD
  Director
  Food and Drug Administration Center for Drug Evaluation and Research (FDA CDER)

### Session 7: Substance Use in Adolescents and Young Adults
Organized and Moderated by Frank J. Vocci, PhD

Problematic substance use and binge drinking often begin in adolescence and young adulthood. Treatments for opioid use disorder are developed in adult populations. Whether the efficacy of opioid use disorder treatments seen in adults translates to similar efficacy in adolescent populations is an empirical question that will be explored. Binge drinking in adolescents and young adults occurs at a time of enhanced neural plasticity and may affect the trajectory of brain development. The effects of binge drinking on brain systems will be discussed and potential approaches to prevent binge drinking will be highlighted.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30 pm - 3:00 pm</td>
<td>Opioid Use Disorder in Adolescents and Young Adults</td>
<td>Wilson M. Compton, MD, MPE</td>
</tr>
<tr>
<td>3:00 pm - 3:30 pm</td>
<td>Prevention of Adolescent Binge Drinking: A Neurodevelopmental View</td>
<td>George F. Koob, PhD</td>
</tr>
<tr>
<td>3:30 pm - 4:00 pm</td>
<td>Refreshment Break</td>
<td>Network with Colleagues, Experts, &amp; Exhibitors</td>
</tr>
</tbody>
</table>

### Session 8: What’s New in Non-Pharmacological Treatments
Organized by Kathleen T. Brady, MD, PhD
Moderated by Richard K. Ries, MD, FAPA, DFASAM

This session will provide a brief description of three commonly utilized non-pharmacologic treatments for addictions: contingency management, 12-Step and technology-enhanced treatment. For all three interventions, data concerning efficacy, predictors of treatment success, and implementation issues will be presented. New research findings will be discussed.
### Saturday, October 13, 2018

#### All Sessions will be held in Grand Ballroom, Ballroom Level

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am - 12:00 pm</td>
<td>Registration &amp; Information Area</td>
<td>Congressional Registration, Ballroom Level</td>
</tr>
<tr>
<td>7:00 am - 7:45 am</td>
<td>Continental Breakfast</td>
<td>Network with Colleagues, Experts, &amp; Exhibitors</td>
</tr>
<tr>
<td>7:45 am - 8:00 am</td>
<td>Opening – Day Three</td>
<td>Introduction &amp; Opening Remarks</td>
</tr>
<tr>
<td>8:00 am - 8:30 am</td>
<td>Overdose, Suicide, and the Gray Areas in Between</td>
<td>Richard K. Ries, MD, FAPA, DFASAM</td>
</tr>
<tr>
<td>8:30 am - 9:00 am</td>
<td>Diagnosis, Prevalence, and Interventions of Self-Harm in Addiction Patient Populations</td>
<td>Hilary S. Connery, MD, PhD</td>
</tr>
<tr>
<td>9:00 am - 9:30 am</td>
<td>Suicide Screening and Intervention in Individuals with Substance Use Disorders</td>
<td>Sanchit Maruti, MD, MS</td>
</tr>
<tr>
<td>9:30 am - 10:00 am</td>
<td>Refreshment Break</td>
<td>Congressional Ballroom A-C, Ballroom Level</td>
</tr>
<tr>
<td></td>
<td>Session 10: Approaches to Treatment of Methamphetamine Use Disorder</td>
<td></td>
</tr>
<tr>
<td>10:00 am – 10:30 am</td>
<td>Compounds and Mechanisms Evaluated Preclinically as Potential Therapeutics for Methamphetamine Disorders</td>
<td>Jane B. Acri, PhD</td>
</tr>
<tr>
<td>10:30 am – 11:00 am</td>
<td>Behavioral/Psychosocial Treatments for Methamphetamine Dependence: Recent Advances</td>
<td>Richard A. Rawson, PhD</td>
</tr>
<tr>
<td>11:00 am – 11:30 am</td>
<td>Medication Development for Treatment of Methamphetamine Use Disorder</td>
<td>Frank J. Voci, PhD</td>
</tr>
<tr>
<td>11:30 am – 12:00 pm</td>
<td>Final Wrap-Up</td>
<td>Wrap-Up, Appreciations, and Adjournment</td>
</tr>
<tr>
<td></td>
<td><strong>Meetings for ASAM Board of Directors</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SATURDAY, OCTOBER 13, 2018</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 pm – 3:00 pm</td>
<td>Finance Committee Meeting</td>
<td>Lafayette, Ballroom Level</td>
</tr>
<tr>
<td>4:00 pm – 9:00 pm</td>
<td>Board of Directors Meeting &amp; Dinner</td>
<td>Renaissance A, Ballroom Level</td>
</tr>
<tr>
<td>8:00 am – 3:00 pm</td>
<td>Board of Directors Meeting</td>
<td>Renaissance A, Ballroom Level</td>
</tr>
</tbody>
</table>
Pre Course Offerings

Faculty
Daniel P. Alford, MD, MPH, FACP, DFASAM
R. Corey Waller, MD, MS, FACEP, DFASAM

THE ASAM Treatment of Opioid Use Disorder Course
Includes waiver qualifying requirements

THE CO*RE/ASAM
Pain Management and Opioids: Balancing Risks and Benefits

12:30 pm – 4:45 pm | Grand Ballroom, Ballroom Level
Course Schedule
12:30 pm – 12:35 pm Welcome and Introductions
12:35 pm – 2:45 pm The Science and The Law
2:45 pm – 3:00 pm REFRESHMENT BREAK
3:00 pm – 4:15 pm Implementing OBOT
4:15 pm – 4:45 pm Case Studies and Q&A

Learning Objectives
• Summarize the clinical pharmacology, efficacy, and safety of methadone, buprenorphine, and naltrexone in treating opioid use disorders
• Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
• Describe procedures for initiating, stabilizing, monitoring, and modifying treatment of patients on buprenorphine or naltrexone
• Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
• Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

Accreditation Council for Continuing Medical Education (ACCME)
ASAM designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ASAM designates this enduring material for a maximum for 4 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)
The American Board of Preventative Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II Requirements.

5:30 pm – 8:00 pm | Grand Ballroom, Ballroom Level
Course Schedule
5:30 pm – 5:40 pm Chapter 1: Welcome
5:40 pm – 5:55 pm Chapter 2: Why are we here
5:55 pm – 6:10 pm Chapter 3: Pain
6:10 pm – 6:30 pm Chapter 4: Assessment
6:30 pm – 6:45 pm Chapter 5: Monitoring and Discontinuing
6:45 pm – 7:00 pm REFRESHMENT BREAK
7:00 pm – 7:15 pm Chapter 6: Special Populations
7:15 pm – 7:25 pm Chapter 7: Federal and State Laws
7:25 pm – 7:35 pm Chapter 8: Counseling Patients
7:35 pm – 7:50 pm Chapter 9: Drug Class Considerations
7:50 pm – 8:00 pm Outcomes, Evaluations, and Questions

Learning Objectives
• Accurately assess patients with pain for consideration of an opioid trial
• Establish realistic goals for pain management and restoration of function
• Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
• Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
• Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
• Educate patients about safe storage and disposal of opioids
• Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice

Accreditation Council for Continuing Medical Education (ACCME)
ASAM designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)
The American Board of Preventative Medicine (ABPM) has approved this activity for a maximum of 2.5 LLSA credits towards ABPM MOC Part II Requirements.
Get the FREE ASAM Events App!

The ASAM Events App is available for download on your mobile devices!

Use the ASAM Events App to:

- View slides
- Take notes during sessions
- Connect with attendees & presenters
- Access the most up-to-date course info
- Mark your favorite interesting sessions

Get Started Now!

Step 1: Go to the iTunes App Store or Google Play and search for "ASAM Events."

Step 2: Click on "The ASAM 2018 State of the Art Course" and create a new account.

Step 3: View the schedule, slides, and posters, take notes, and more.

Step 4: To sync with updated conference info, located the menu in the top right corner.

Click "Refresh Schedule" in the "Your Event" section of the menu.

Questions? Visit the ASAM Information Desk

---

**e-LEARNING CENTER & Claiming CME**

**Claim your CME** anytime between the end of the conference and October 2021!

**State of the Art Course and Pre-Course Attendees:**

1. Go to eLearning.ASAM.org
2. After logging in, select “Dashboard” from the right-hand menu (on mobile devices, you will find “Dashboard” by clicking the three horizontal lines in the header).
3. Locate “Packages” and select the name on the Course.
4. Click “Content”.
6. Find the box that says “Evaluation” and click the blue button that says, “Fill out Survey.”
7. After you have completed the survey, select the box labeled “Live Credit – Attended In-Person” and click the blue button that says, “Claim Medical Credits.”
8. Select “Physician – Live” or “Non-Physician – Live” and the number of hours you attended, then click “Submit.”
9. Print out your certificate or save it to your device.

**Helpful Tips**

**Getting to the e-LC:**

Go to: elearning.ASAM.org or click "eLearning Center" in the Course App

**Logging-in:**

Use your email address and ASAM password. If you do not remember your password, request a rest by selecting “Forgot Password” from the log-in screen

**How-to Video Series:**

Check out our helpful how-to video series with tips and tricks for navigating the eLC. New videos added regularly.

Watch the videos at: eLearning.ASAM.org/faqs

**WATCHING SESSIONS ON-DEMAND:**

Relive the course! Course registrants of The ASAM 2018 State of the Art Course gain FREE access to sessions on-demand in the ASAM e-Learning Center within 30 days of the course.
Abbvie | 17
8203 Westwood Mews Ct.
Vienna, VA 22182
703-850-6660
www.abbvie.com
Abbvie is a biopharmaceutical company which provides HCV medication.

Alkermes Inc. | 9
852 Winter St.
Waltham, MA 02451
781-609-6366
www.alkermes.com
Alkermes is a biopharmaceutical company that develops innovative medicines designed to help patients with serious, chronic conditions better manage their disease.

ASAM CONTINUUM, The ASAM Criteria Decision Engine | 11
11400 Rockville Pike, #200
Rockville, MD 20852
301-656-3920
www.ASAMcontinuum.org
Developed after more than 20 years of research, ASAM CONTINUUM is a comprehensive assessment tool that helps clinicians organize treatment priorities, produce accurate ASAM Criteria dimensional assessments, and recommend effective level of care placements.

Aventic LLC | 18
11300 Space Blvd Suite 2-B
Orlando, FL 32837
917-254-8878
www.elevareskin.com

Banner Health: Banner University Medical Center – Phoenix | 13
1630 17th Avenue
Greeley, CO 80531
970-810-2075
www.bannerhealth.com
Banner Health: Banner University Medical Center – Phoenix Addiction Medicine: Full range of services including Level II Neonatal ICU and largest admitting medical toxicology services in US.

BestNotes | 7
PO Box 5578
Twin Falls, ID 83301
855-489-1792
www.bestnotes.com
BestNotes is a HIPAA compliant Customer Relationship Management and Electronic Health Record database system specifically designed for the behavioral health and substance abuse industry.

Cox Health | 8
1001 E Primrose
Springfield, MO 65807
800-869-4201
www.coxhealth.com
CoxHealth, a not-for-profit healthcare system in southwest Missouri, is seeking physicians for an excellent opportunity in our Outpatient Addiction Medicine clinic in Springfield, MO.

Gilead Sciences, Inc. | 3
333 Lakeside Dr.
Foster City, CA 94404
650-574-3000
www.gilead.com
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

Kaleo | 5
111 Virginia Street, Suite 300
Richmond, VA 23219
804-998-1501
www.kaleo.com

McLean Hospital | 4
115 Mill Street, Mail Stop 115
Belmont, MA 02478
800-906-9531
www.mcleanhospital.org/signaturerecovery
Harvard Medical School-affiliated McLean Hospital offers comprehensive care and specialized treatment plans for individuals who are living with substance use and co-occurring disorders. Call 800.906.9531.

Medical Disposables | 1
4855 Distribution Ct, Suite 11
Orlando, FL 32822
772-359-4655
www.medicaldispposables.us
Medical Disposables provides the highest quality and most advanced line of CLIA waived rapid screening drug tests on the market.

National Institute on Alcohol Abuse & Alcoholism | 6
5635 Fishers Lane, Rm 3095
Rockville, MD 20892
301-443-0596
www.niaaa.nih.gov
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) exhibit highlights materials and most advanced line of CLIA waived rapid screening drug tests on the market.

New Season | 2
2500 Maitland Center Pkwy, Suite 230
Maitland, FL 32751
407-385-2898
www.newseason.com
New Season is the 2nd largest provider of opioid addiction treatment in the U.S. successfully treating patients with superior quality care for thirty years.

Orexo | 12
150 Headquarters Plaza, East Tower, 5th Floor
Morristown, NJ 07960
973-936-6910
www.zubsolv.com
Orexo US, Inc., is a specialty pharmaceutical company with a mission to advance the treatment of opioid dependence and support patient care.

Pathway Healthcare | 16
2911 Turtle Creek Blvd
Dallas, Texas 75219
(205) 495-7939
www.pathwayhealthcare.com
Pathway Healthcare provides highly effective, lasting treatment for opioid and other substance abuse disorders utilizing scientifically proven methods and medications in a supportive, professional outpatient environment.

SMART Recovery | 15
2575 Pine Tree Dr
Miami Beach, FL 33140
508-733-6469
www.smartrecovery.org
SMART Recovery, 501c3, promotes a science-based, self-empowering, abstinence-oriented, free, mutual aid program with 2,800 meetings in 23 countries. The SMART Program is endorsed by most Federal agencies. About 300 people per month take the SMART Facilitator Training Program, 2/3 professionals. The SMART Recovery Handbook has been published in 12 languages.

US WorldMeds | 14
4441 Springdale Rd
Louisville, KY 40241
502-815-8175
www.usworldmeds.com
US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs.

Wolters Kluwer | 10
Two Commerce Sq, 2001 Market St
Philadelphia, PA 19103
215-521-8300
www.lww.com
World wide publishers of medical text, journals, and multimedia.
Jane B. Acri, PhD  
Chief, Medication Discovery and Toxicology Branch  
Division of Therapeutic and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health  
Bethesda, MD

Daniel P. Alford, MD, MPH, FACP, DFASAM  
Professor  
Boston University School of Medicine  
Boston, MA

Michael H. Baumann, PhD  
Chief, Designer Drug Research Unit  
National Institute on Drug Abuse, National Institutes of Health  
Baltimore, MD

Antonello Bonci, MD  
Scientific Director  
National Institute on Drug Abuse, National Institutes of Health  
Baltimore, MD

Eduardo R. Butelman, PhD  
Research Associate Professor  
Laboratory on the Biology of Addictive Diseases, Rockefeller University  
New York, NY

D. Faye Caldwell, JD  
Managing Partner  
Caldwell Everson PLLC  
Houston, TX

Anthony Campbell, RPH, DO, CDR, USPHS  
Medical Officer/Consultant  
Center for Substance Abuse Treatment - SAMHSA  
Rockville, MD

Grace Chang, MD, MPH  
Professor of Psychiatry  
Harvard Medical School/VA Boston  
Weston, MA

Wilson M. Compton, MD, MPE  
Deputy Director  
National Institute on Drug Abuse, National Institutes of Health  
Rockville, MD

Hilary S. Connery, MD, PhD  
Assistant Professor  
McLean Hospital/Harvard Medical School  
Belmont, MA

Richard C. Dart, MD, PhD  
Director, Rocky Mountain Poison and Drug Center  
Denver Health and Hospital Authority  
Aurora, CO

Anita Everett, MD  
Chief Medical Officer  
Substance Abuse and Mental Health Services Administration  
Rockville, MD

Susan R. George, MD, FRCPC, FACP  
Professor of Medicine and Pharmacology  
University of Toronto  
Thornhill, Ontario, CAN

Kevin M. Gray, MD  
Professor, Department of Psychiatry and Behavioral Sciences  
Medical University of South Carolina  
Charleston, SC

Deborah S. Hasin, PhD  
Professor  
Columbia University Medical Center  
New York, NY

George F. Koob, PhD  
Director  
National Institute on Alcohol Abuse and Alcoholism  
Rockville, MD

Dustin C. Lee, MS, PhD  
Instructor  
Johns Hopkins University School of Medicine  
Baltimore, MD

Joshua D. Lee, MD, MSc  
Associate Professor  
NYU Langone Medical Center  
New York, NY

Lisa A. Marsch, PhD  
Professor of Psychiatry, Center for Technology and Behavioral Health  
Geisel School of Medicine at Dartmouth College  
Lebanon, NH

Sanchit Maruti, MD, MS  
Assistant Professor  
University of Vermont Medical Center  
Burlington, VT

Mary E. McCaul, PhD  
Professor, Department of Psychiatry and Behavioral Sciences  
Johns Hopkins University School of Medicine  
Baltimore, MD

Maxwell L. Stitzer, PhD  
Professor, Department of Psychiatry and Behavioral Sciences  
Johns Hopkins University School of Medicine  
Baltimore, MD

Ryan G. Vandrey, PhD  
Associate Professor  
Johns Hopkins University School of Medicine  
Baltimore, MD

Frank J. Vocci, PhD  
President and Senior Research Scientist  
Friends Research Institute, Inc.  
Baltimore, MD

R. Corey Waller, MD, MS, FACEP, DFASAM  
Principal  
Health Management Associates  
Lansing, MI

Alexander Y. Waller, MD, MSc, FASAM  
Director, Addiction Medicine Fellowship  
Clinical Addiction Research and Education Unit  
Boston Medical Center  
Boston, MA

Constance M. Weisner, DrPH, LCSW  
Associate Director, Behavioral Health, Aging and Infectious Diseases  
Division of Research, Department of Psychiatry  
University of California, San Francisco  
Oakland, CA

Janet Woodcock, MD  
Director, Center for Drug Evaluation and Research  
Food and Drug Administration  
Silver Spring, MD
Celebrating 50 Years of Quality Education!

The ASAM 50th Annual Conference is the nation's premiere event showcasing the latest innovations and scientific developments in addiction medicine.

Discover 50 Reasons Why You Should Attend:

- Experience awe-inspiring keynote addresses, policy updates, and national perspectives from leaders in the field, as well as inspirations from award winners on their contributions to addiction medicine.

- Learn from the latest scientific research and best clinical practices in addiction medicine presented at over 50 educational sessions.

- Join the largest gathering of physicians and healthcare professionals (over 2,200!) dedicated to addiction medicine and the treatment of patients with substance use disorders.

And So Many More!

Sign-up for Additional Pre-Conference Offerings
Thursday, April 4, 2019

Find more reasons to attend:
www.TheASAMAnnualConference.org